Business
Peijia Medical Announces 2025 Interim Results
Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025.
About this update from Peijia Medical Ltd.
[{"type":"text","content":"HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025.","length":315,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Peijia Medical)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Peijia Medical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pHSM1YpXq0qVN5y.SIsBsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2166853/PEIJIA_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Group reported sustained revenue growth and significantly improved expense ratios, driving a structural enhancement in profitability. Revenue reached RMB353.4 million, up 17.3% period-to-period. Revenue composition remained stable, with TAVR-related products and neurointerventional products accounting for 45.7% and 54.3%, respectively.","length":341,"tagName":"p"},{"type":"text","content":"Revenue from TAVR-related products increased 24.0% to RMB161.6 million, fueled by market share gains in China's transfemoral TAVR market and a favorable product mix shift toward newer premium products. Neurointerventional product revenue grew 12.2% to RMB191.8 million, supported by deeper penetration of key products and the successful launch of the YonFlow® Flow Diverting Stent.","length":385,"tagName":"p"},{"type":"text","content":"Leveraging economies of scale and lean management, the Group substantially improved operational performance. The Neurointerventional Business segment profit increased 42.4% to RMB40.9 million, while the segment loss of the Transcatheter Valve Therapeutic Business narrowed 35.3% to RMB76.1 million. Excluding the total loss of the corresponding entities of the Future Technology Business, the net loss of the Group's core business[1] narrowed 52.4% period-to-period to RMB30.7 million.","length":489,"tagName":"p"},{"type...